T he retinoic acid-related orphan receptors g (RORg) and gT (RORgT) are products of the RORC gene transcribed from different transcription start sites under the control of independent promoters (1-4). These two nuclear hormone receptors differ in their amino acid sequences by 13 aa residues in the Nterminal region. The basic RORC variant (RORg) is expressed ubiquitously and plays an important function in the regulation of development and metabolism (5) . Recently, the 7-oxygenated sterol was identified as an endogenous ligand modulating the function of this transcription factor (6) . The expression of RORgT (also termed RORC2) has a very restricted pattern, and its product is predominantly found in immune organs, such as thymus, and in particular lineages of immune cells, such as immature doublepositive thymocytes and Th17 lymphocytes (2, 7) , where this transcription factor plays important functions in the maturation of a/b T cells and the differentiation of Th17 cells, respectively (2, 8) . Th17 cells are a subset of Th cells capable of expressing the proinflammatory cytokine IL-17 (9) (10) (11) . This cytokine, which is also expressed by several other immune cells such as g d T cells (12) and mast cells (13) , exercises its function by triggering the IL-17RA, which is ubiquitously expressed in multiple cell types (14) . IL-17RA engagement triggers a signaling cascade leading to the activation of the transcription factors NF-kB and AP1, which are major regulators that mediate changes in the expression of the genes responsible for initiating and maintaining an inflammatory state (14) . The genes upregulated by IL-17 include cytokines, such as IL-6, and chemokines, such as IL-8, Rantes, and GRO (15) (16) (17) . IL-17 expression is a major phenotypic marker of Th17 cells that are capable of initiating an immune response that is distinct from those driven by Th1 and Th2 (18, 19) . The Th17-driven immune response provides effective protection against certain extracellular pathogens (20, 21) and is also responsible for the development of inflammatory processes associated with several human diseases, including autoimmune and allergic conditions (22, 23) , atherosclerosis (24) , liver dysfunctions (25) , and tumors (26) . Differentiation of naive CD4 + lymphocytes into Th17 cells is supported by the coordinated action of several cytokines, including IL-6, IL-23, and TGF-b (23) . RORgT mRNA levels increase upon Th17 expansion in vitro, and increased RORgT mRNA levels in tissues positively correlate with Th17 activity observed in different inflammatory diseases (27) (28) (29) . Mechanisms regulating the tissue-specific expression of RORgT are not well understood. Studies with knockout mice revealed the involvement of the transcription factors STAT3, IFN regulatory factor 4, and v-rel reticuloendotheliosis viral oncogene homolog (c-Rel) in the upregulation of RORgT (4, (30) (31) (32) . The mechanism by which RORgT transcripts are transcriptionally regulated in human cells is largely unknown. Our investigation of the transcriptional regulation of RORgT in human lymphocytes revealed that the transcription factors upstream stimulatory factor 1 (USF-1) and USF-2 are indispensable for the transcription of RORgT, and that the upregulation of USFs occurs in differentiating Th17 cells in parallel with the upregulation of RORgT and IL-17.
Materials and Methods

Cell culture
Jurkat (human T cell lymphoblast-like), HeLa (cervix carcinoma), and HepG2 (hepatocellular carcinoma) cell lines were obtained from American Type Culture Collection (Manassas, VA). They were maintained under standard conditions in RPMI 1640 or DMEM containing 10% FBS at 37˚C in a 5% CO 2 atmosphere.
Real-time RT-PCR
RNA was isolated from cells using TRI Reagent (Molecular Research Center, Cincinnati, OH) and reverse-transcribed with the Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific/Fermentas, Vilnius, Lithuania). Real-time RT-PCR amplification was carried out on a LightCycler 480 (Roche, Basel, Switzerland) using SYBRGreen I Master Mix (Roche) as follows: 5 min at 95˚C and then 45 cycles each at 95˚C for 10 s, 60˚C for 10 s, and 72˚C for 10 s. Sequence of GATA-3 primers were published by Hoene et al. (33) . Other intron-spanning primers used to detect cDNA sequences were designed using Primer3 software: RORgT forward, 59-CTGCTGAGAAGGACAGGGAG-39; RORg forward, 59-CA-CAGAGACAGCACCGAGC-39; RORgT/RORg reverse (same for both isoforms), 59-AGTTCTGCTGACGGGTGC-39; USF-1, 59-AATTGCCC-CTAGGACTCACC-39 (forward) and 59-ACAAGCGGTGGTTACTCTGC-39 (reverse); USF-2, 59-TGATCCAAAATCCCTTCAGC-39 (forward) and 59-TCTTCTCCTCTCATCTCGGG-39 (reverse); and IL-17A, 59-AAAC-AACGATGACTCCTGGG-39 (forward) and 59-CTTGTCCTCAGAATT-TGGGC-39 (reverse). D cycle threshold values were transformed into relative copy number values (the number of copies of cognate mRNA per housekeeping gene index, calculated as the averaged cycle threshold of the housekeeping genes hypoxanthine phosphoribosyltransferase 1 [HPRT1], hydroxymethylbilane synthase [HMBS], and ribosomal protein LI3a
[RPLI3A]) as described in our previous study (34) .
RORgT promoter constructs and transfection
Fragments of RORgT spanning its putative promoter region were prepared by PCR amplification of human genomic DNA and cloned into a pUC18 vector using HincII, a blunt restriction endonuclease. The following primers were used for amplification: reverse primer, 59-CTGTTAAGCTTA-CATCCTCCTTTCCAGAGGG-39 (position +78; all nucleotide locations are reported relative to the A in the ATG translation initiation codon) and forward primers, 59-AGGATTGGTACCTCCACATAAAACATCGAGAA-CC-39 (position 2869), 59-CAGGCGGTACCACACTGGGTATGGCTGT-TGG-39 (position 2589), 59-ACCGCGGGTACCTGTCGCATGTGGTTT-TGG-39 (position 2341), and 59-GCCACCGGTACCGTGCAGAGCTT-AAACCCCC-39 (position 2180). The sequences of the cloned inserts were verified by automated sequencing and then recloned into pGL3-Basic vector (Promega, Madison, WI) using Acc65I/HindIII restriction endonucleases. Exgene500 from Fermentas was used for the transfection of HeLa and HepG2 cells. Jurkat cells were transfected with Fugene HD (Roche). Luciferase measurements were performed on an Infinite 200 PRO (Tecan, Männedorf, Switzerland) and standardized as described previously (34) . Expression vectors coding various transcription factors were purchased from OriGene Technologies (Rockville, MD) with the exception of USF-1 (Open Biosystems, Lafayette, CO).
Site-directed mutagenesis
Mutagenesis was performed directly on plasmids (pUC18) containing sequences 2589/+78 and 2341/+78 of RORgT promoter using the PCRbased method followed by removal of the template by DpnI digestion. Introduced mutation of the E-BOX sequence was based on a previous work of Ciccone et al. (35) . For mutagenesis, the following primer pairs were used: 59-TCCACAGGGTGTACGGTAGCACATGCCACCACC-39 (m4f) and 59-GGTGGTGGCATGTGCTACCGTACACCCTGTGGA-39 (m4r); 59-GTCCCTGAAGTACCCTAGCAAAGAGGGTCAGGC-39 (m3f) and 59-GCCTGACCCTCTTTGCTAGGGTACTTCAGGGAC-39 (m3r); 59-CCC-AGATTGGCACCGTAGGGCGCCTGTCATCCT-39 (m2f) and 59-AGGA-TGACAGGCGCCCTACGGTGCCAATCTGGG-39 (m2r); and 59-GGTG-GGGGGTTGTACCTTAGCCACCTGTGTGGT-39 (m1f) and 59-ACCAC-ACAGGTGGCTAAGGTACAACCCCCCACC-39 (m1r). The mutated sequences were verified by sequencing and then recloned into pGL3-Basic vector.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation with normal mouse IgG (Millipore, Billerica, MA), anti-USF-1 (H-86; Santa Cruz, Santa Cruz, CA), anti-USF-2 (H-100, Santa Cruz), and anti-c-Myc (9E11; Santa Cruz) was performed using the EZ-ChIP kit (Millipore) according to the manufacturer's protocol. PCR amplification was performed using 2 ml DNA with primers specific to the RORgT promoter (forward: 59-AGGCTGCACCACACTGG-39, position 2599; reverse: 59-TTCTACTCCTCCTACCCCCG-39, position: 2429) for 36 cycles, and the ganglioside-induced differentiation-associated protein (GDAP1) promoter (36) was used as a negative control for 32 cycles. The amplification of soluble chromatin before immunoprecipitation was used as an input control. PCR products were resolved on a 1.5% agarose gel and stained with ethidium bromide.
EMSAs
Nuclear extracts were prepared as described elsewhere (37) and subsequently used in EMSA. Infrared dye-labeled annealed oligonucleotides were incubated with 1 mg nuclear extract in binding buffer containing 10 fmol infrared dye-labeled probes, 5 mM Tris-HCl (pH 8.0), 50 mM NaCl, 5 mM DTT, 5 mM MgCl 2 , 0.5% Igepal, 25% glycerol, 100 mM ZnCl 2 , and 0.2 mg salmon testis DNA in a 20-ml reaction volume. For the competition assay, 10-and 50-fold molar excesses of unlabeled oligonucleotides (wt, m4, m3, m2, or m1) were added to the reaction mixture. The reactions were incubated on ice for 60 min before probe addition, followed by an additional 30-min incubation. The binding reactions were resolved by electrophoresis on a 5% polyacrylamide gels in 0.5% Tris-acetate EDTA buffer. The products were then imaged on an Odyssey (LiCor, Lincoln, NE) infrared fluorescence scanner. Anti-USF-1 (H-86; Santa Cruz) and anti-USF-2 (H-100; Santa Cruz) Abs were used for supershift experiments.
Naive CD4 + T cell isolation and differentiation
The protocol used in this study was described in detail by Wilson and colleagues (23): PBMCs were isolated from buffy coats obtained from healthy donors and centrifuged through Ficoll, and the naive CD4 + fraction was then isolated using the CD4 + T Cell Isolation Kit II (Miltenyi Biotec GmbH Bergisch, Gladbach, Germany). Naive CD4 + T cells were maintained in Yssel's media containing human AB serum for 5 d in Th17 polarizing conditions with beads coated with anti-CD2, anti-CD3, and anti-CD28 (T Cell Activation/Expansion Kit; Miltenyi Biotec), and with a cytokine mixture containing human IL-1b (50 ng/ml), human IL-6 (30 ng/ ml), human IL-23 (10 ng/ml), and human TGF-b (10 ng/ml). The cytokines were purchased from R&D Systems (Minneapolis, MN).
Analysis of IL-17 production
For the analysis of IL-17 production, CD4 + T cells and CD4 + cells stimulated with the T Cell Activation kit, in the presence or absence of the cytokine mixture, were cultured for 5 d. The cells and supernatants were collected for RNA isolation and ELISA assays, respectively. ELISA was conducted using the Quantikine Human IL-17 Immunoassay kit (R&D Systems) according to the manufacturer's protocol. Measurements were performed at 450 nm using a Sunrise microplate reader (Tecan).
Small interfering RNA and nucleofection
Duplexes of Stealth small interfering RNA (siRNA) against the USF-1 (USF1HSS144431) and USF-2 (USF2HSS144434) transcripts were purchased from Invitrogen (Carlsbad, USA). Negative control siRNA-A with a scrambled sequence was purchased from Santa Cruz. Jurkat cells were nucleofected with 100 pmol of each target siRNA duplex using Amaxa SE Cell Line for 4D-Nucleofector X Kit L (Lonza, Basel, Switzerland) according to the manufacturer's protocol. After nucleofection, the cells were cultured for 96 h and then collected for RNA extraction. Th17 cells differentiated in vitro from naive CD4 + were nucleofected with the same siRNA duplexes as described earlier using Amaxa P3 Primary Cell 4D-Nucleofector X Kit (Lonza) according to the manufacturer's instruction. After nucleofection, the Th17 cells were cultured in the Yssel's medium without cytokines for 16 h. This was followed by addition of cytokine mixture containing IL-1b (50 ng/ml), IL-6 (30 ng/ml), IL-23 (10 ng/ml), and TGF-b (10 ng/ml), and beads coated with anti-CD2, anti-CD3, and anti-CD28 and culture for an additional 5 d.
Computational analysis and statistics
Putative transcription factor elements within the RORgT gene promoter were identified using MatInspector software (38) . Alignment of the RORgT promoters from various mammalian species was performed using the CLUSTALW program (39) . Genomic sequences were downloaded from the University of California Santa Cruz genome browser (40) . Statistical analysis was performed using paired t test or one-way ANOVA, followed by Dunn's post hoc test. A p value #0.05 was considered statistically significant.
Results
Tissue-specific expression of RORC gene variants
The expression of two known variants of the RORC gene was first analyzed in selected cell lines. HepG2 hepatocytes and cervix cell carcinoma HeLa cells almost exclusively expressed RORg, whereas Jurkat lymphocytes predominantly expressed RORgT (Fig. 1A) .
Analysis of the human RORgT promoter activity
Next, a series of 59-deletion mutants of the human RORgT promoter cloned into a luciferase reporter construct was used to analyze promoter activity in Jurkat lymphocytes and identify the responsible sequences. The transfection of Jurkat lymphocytes with RORgT promoter constructs resulted in significant promoter activity, with the highest activity observed for constructs containing the sequences spanning from 2340 to +78 (Fig. 1B) . The shortest analyzed sequence (2180/+78) and constructs representing sequences further 59 upstream of the RORgT translation start site also exhibited significant activity compared with the promoterless pGL3-Basic vector. The promoter activities in nonlymphatic cells (HepG2 hepatocytes and HeLa cells) were several fold lower than that observed in Jurkat lymphocytes. The longest promoter construct (2869/+78) had the highest activity.
Screening for transcription factors interacting with human RORgT promoter
Several transcription factors were then overexpressed in HeLa cells cotransfected with the longest reporter construct. Overexpression of USF-1 and USF-2, but not the other tested transcription factors, resulted in a significant (2.1-and 2.9-fold, respectively) increase in human RORgT promoter activity (Fig. 2) . Analysis of the 59-upstream sequences of the human RORgT gene revealed four binding sites for USF-1 and USF-2 (E-BOX 1-4) that are preserved among mammalian species (Fig. 3) .
Effect of USF-1 and USF-2 overexpression on activity of human RORgT promoter Next, the effect of USF-1 and USF-2 overexpression on the activities of different human RORgT promoter constructs was assessed. Overexpression of USF-1 and USF-2 did not change the activity of the shortest promoter construct (2180/+78), which does not contain a USF binding motif (Fig. 4A) . In contrast, the activity of the promoter construct containing sequences 2340 to +78, which overlap the E-BOX 1 and 2 sites, was significantly upregulated. The activities of the two longer promoter constructs (2869/+78 and 2589/+78), which overlap all four USFs binding sites (E-BOX 1-4), were upregulated slightly higher than the activity of phRORgT(2341/+78)Luc. To gain further insights into the role of USF in the regulation of RORgT, we used additional promoter constructs (2589/+78) with mutations in E-BOX 3 alone, E-BOX 4 alone, or both E-BOX 3 and E-BOX 4 in a series of transfection experiments in HeLa cells. Mutation of E-BOX 4, the most distal site, enhanced the responses elicited in HeLa cells by overexpressed USF-2 but did not change the response caused by overexpressed USF-1 (Fig. 4B) . In contrast, mutation of E-BOX 3 resulted in a small but significant decrease in response to USF-1 overexpression and did not alter the level of upregulation caused by USF-2 overexpression. The construct containing both mutations enhanced the response to USF-2 overexpression and caused a small decrease in response to USF-1 overexpression. When a similar analysis was performed using the construct phRORgT (2341/+78)Luc containing E-BOX 1 and E-BOX 2 and additional constructs with mutations in E-BOX 1 alone, E-BOX 2 alone, or both, the data showed a different pattern of effects on RORgT promoter activity following the overexpression of USF-1 and USF-2 (Fig. 4C) . Thus, mutation of each of these two binding sites resulted in a significant decrease in promoter activity following the overexpression of USF-1 and USF-2. Mutation of both EBOXes resulted in promoter activity that was significantly lower than that observed in the presence of either alone. The promoter activities of mutated and wild type phRORgT(2341/+78)Luc and phRORgT (2589/+78)Luc promoter constructs were compared in Jurkat lymphocytes. In the longer construct (2589/+78), mutation of E-BOX 3 alone or E-BOX 3 and E-BOX 4 (but not E-BOX 4 alone) resulted in a small but detectable decrease in promoter activity in the Jurkat lymphocytes (Fig. 4D) . Mutations in phRORgT(2341/+78)Luc, which depleted this construct of the more distally located E-BOX 2 USF binding site, strongly (.2-fold) decreased promoter activity. Mutation of E-BOX 1 resulted in a significant but small (10%) decrease in promoter activity, and double mutation of E-BOX 1 and E-BOX 2 resulted in promoter activity comparable with those observed with the single E-BOX 2-deficient mutant.
FIGURE 5. Binding of USF-1 and USF-2 to the human RORgT gene promoter. (A-D) Nuclear extracts were prepared from resting Jurkat cells as described in Materials and Methods. EMSAs were performed using infrared (IR) fluorescently labeled oligonucleotide probes and unlabeled "cold" oligonucleotides of indicated sequences. For the competition assay, the "cold" competitor oligonucleotides with wild-type (wt) or mutated (m4, m3, m1, or m2) sequences were added at indicated molar fold excess over the amount of the labeled probe. For supershift assay, anti-USF-1 and anti-USF-2 Abs were added to the reaction mixture as indicated. (E) Results of chromatin immunoprecipitation performed on living Jurkat cells. Chromatin was isolated from resting Jurkat cells fragmented and immunoprecipitated with normal mouse IgG, anti-USF-1, anti-USF-2, and anti-c-Myc Abs. Immunoprecipitated DNA sequences were amplified by PCR with primers specific to the RORgT promoter and GDAP1 promoter (negative control), and visualized on agarose gel stained with ethidium bromide. NS, Nonspecific; S, shift; SS, supershift.
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Analysis of interaction of USFs with human RORgT promoter sequences
To confirm that USFs regulate RORgT promoter activity in Jurkat lymphocytes, EMSA assays were performed using Jurkat lymphocyte nuclear extracts and nucleotide probes matching the sequences of E-BOX 1-4. Incubation of the Jurkat-derived nuclear extract with all four nucleotide probes resulted in the detection of specific bands that were competed out with an excess of cold nucleotide of matching but not with mutated sequences (Fig. 5) . The addition of Abs against USF-1 and USF-2 resulted in the appearance of additional bands representing supershifts. For the E-BOX 4 nucleotide (Fig. 5A) , the weak but detectable supershift band appeared following the addition of anti-USF-2, but not anti-USF-1 Ab. For the E-BOX 3 nucleotide (Fig. 5B) , in contrast, a supershift band appeared after the addition of anti-USF-1, but not anti-USF-2 Ab. Supershift experiments with nucleotide probes matching the sequences of E-BOX 2 and E-BOX 1 (Fig. 5C, 5D ) generated similar extra bands with both anti-USF-1 and anti-USF-2 Ab. Thus, the USF-1 and USF-2 proteins in the nuclear extract of Jurkat lymphocytes interacted with all four tested USF-binding motifs in vitro. The interaction of USF-1 and USF-2 with the RORgT promoter was then investigated in intact Jurkat lymphocytes. Chromatin immunoprecipitation experiments revealed the binding of both USF-1 and USF-2 but not v-myc myelocytomatosis viral oncogene homolog (c-Myc; used as negative control) proteins to the RORgT promoter (Fig. 5E ). In addition, USF-1 and USF-2 did not bind to the control GDAP1 promoter, which does not contain USF binding motifs.
Effect of inhibition of USFs on RORgT expression in Jurkat cells
To confirm the functionality of USFs binding to the RORgT promoter, we used siRNAs targeting USF-1 and USF-2. The transfection of Jurkat cells with siRNAs targeting USF-1 and USF-2 resulted in a significant and targeted gene-specific decrease in the respective mRNA levels (Fig. 6A, 6B ). Jurkat cells treated with siRNAs targeting USF-1 alone, USF-2 alone, and both transcripts showed RORg mRNA (data not shown) and GATA-3 mRNA (Fig.  6C ) levels similar to those seen in control cells. In contrast, Jurkat cells treated with siRNAs targeting USF-1 alone, USF-2 alone, or both transcripts showed significantly lower RORgT mRNA levels (Fig. 6D) . The USF-2 siRNA inhibited RORgT expression more than the USF-1 siRNA, with the combination of both siRNAs having the strongest inhibitory effect (65% decrease).
Effect of inhibition of USFs on RORgT expression in human Th17 cells
To gain evidence of USF involvement in the regulation of RORgT expression in Th17, the standard experimental protocol for in vitro differentiation of Th17 cells from peripheral blood naive CD4 + lymphocytes was used. The culture of naive CD4 + lymphocytes in the presence of a standard cytokine mixture combined with activation by cross-linking of CD2, CD3, and CD28 resulted in the accumulation of a significant amount of IL-17 in the supernatant (2.1 6 0.9 pg/ml for CD4 + and 403.1 6 103.8 pg/ml for Th17, statistically significant difference at p , 0.05) in parallel with an increase in IL-17 mRNA in the cell pellet (Fig. 7A) . As expected, the differentiation of Th17 from CD4 + was also associated with a significant upregulation of RORgT mRNA (Fig. 7B) , but not RORg mRNA (Fig. 7C) and GATA-3 (Fig. 7D ) in these cells. Interestingly, this in vitro differentiation process was associated with significant upregulation of USF-1 and USF-2 mRNA (Fig. 7E,  7F ). To further confirm the role of USFs in RORgT expression, Th17 cells obtained in vitro from CD4 + lymphocytes were nucleofected with siRNAs targeting USF-1 and USF-2, and cultured for additional 5 d under optimal conditions. As shown in Table I , this treatment inhibited USF-1 and USF-2 expression and resulted in a significant decrease in the level of RORgT mRNA. The expression of RORg, GATA-3, and IL-17 were not significantly inhibited.
Discussion
The transcriptional regulation of RORgT, one of the two RORC variants, is an important element of the regulation of Th17 differentiation. Most data regarding the tissue-specific expression of RORgT and its transcriptional regulation come from murine studies. Similar to those of the mouse, the two variants of the human RORC gene originate from different transcription start sites and are regulated by different promoters. There was a cell line- (Fig. 1A) and cell lineage-specific (data not shown) pattern of expression of RORg and RORgT. Also like the mouse, human RORgT is preferentially expressed in selected lymphocytic lineages but is hardly detectable in nonlymphatic cells (Fig. 1A, Fig.  7B , data not shown). This preferential expression of RORgT in human Jurkat lymphocytes and peripheral blood-derived CD4 + Th17 cells was associated with a very low expression of RORg that is similar to the previously reported pattern of RORg/RORgT expression in murine thymocytes (2) and different from the pattern observed in murine Th17 cells, in which high expression of RORgT was associated with comparable levels of RORg (4). This tissue-specific pattern of expression is consistent with the results of promoter activity analysis, which showed that RORgT promoter constructs had significantly higher activity in Jurkat T lymphocytes than in nonlymphatic cells (Fig. 1B) . Although significant promoter activity in Jurkat lymphocytes was observed with sequences spanning 2180 bp 59 upstream of RORgT, the highest activity was mediated by sequences further upstream, up to 2340 bp relative to the RORgT translation start site (Fig. 1B) . To our knowledge, this represents the first analysis of human RORgT promoter activity. Our observations are consistent with the hypothesis that preferential transcription of the RORgT promoter in T cells participates in the tissue-specific expression of RORgT in human T cells. Previously, a similar upstream sequence (2400 to +151) of murine RORgT showed significant promoter activity in murine EL-4 lymphocytes (4). Screening for transcription factors that upregulate the human RORgT promoter revealed possible roles for USF-1 and USF-2 in the regulation of human RORgT expression (Fig. 2) . This regulation could be mediated by four USF binding sites, E-BOX 1-4, in the promoter region that are preserved in several mammalian species (Fig. 3) . In situ mutation analysis of promoter constructs (Fig. 4) and gel shift experiments (Fig. 5A-D) confirmed that these binding sites can bind USF-1 and USF-2 and are necessary for mediating the effects of USF-1 and USF-2 on the activity of the RORgT promoter. Although the proximal binding sites (E-BOX 1 and E-BOX 2) seemed to mediate a strong upregulation of promoter activity by both USF-1 and USF-2, the distal binding sites (E-BOX 3 and E-BOX 4) seemed to preferentially bind USF-1 and USF-2, respectively, and upregulate (E-BOX 4) or downregulate (E-BOX 3) promoter activity. This observation is consistent with the pattern of 59-deletion promoter construct activities in Jurkat cells, in which the two constructs containing E-BOX 4 had significantly lower activity compared with the construct containing only E-BOX 1 and E-BOX 2 (Fig. 1B) . Additional experimental data obtained using Jurkat lymphocytes strongly suggest that high RORgT promoter activity and high RORgT mRNA expression depend on USF-1 and USF-2 expression in those cells. Thus, Jurkat lymphocytes expressed 2-to 3-fold Naive CD4 + fraction was isolated from PBMCs obtained from healthy donors using immunomagnetic beads and cultured for 5 d under Th17 polarizing conditions as described in Materials and Methods. Differentiated Th17 cells were nucleofected with control siRNA-A with scrambled sequence and mixture of siRNA duplexes targeting USF-1 and USF-2. After nucleofection, Th17 cells were cultured for additional 5 d under optimal conditions and collected for RNA extraction. Expression of selected genes was determined by real-time RT-PCR and normalized to the housekeeping gene index (HPRT1, HMBS, and RPLI3A). Data are presented as mean 6 SEM from six independent experiments performed using cultures originated from six different donors (n = 6). Analysis of IL-17 production was determined using the Quantikine Human IL-17 Immunoassay kit (R&D Systems). more USF-1 and USF-2 than nonlymphatic cells (data not shown). USF-1 and USF-2 preferentially occupied RORgT promoter DNA (Fig. 5E) , and suppression of the expression of USF-1 alone, USF-2 alone, or both USFs significantly decreased the level of RORgT mRNA (Fig. 6 ). Taken together, these observations suggest that human RORgT is transcriptionally regulated by USF-1 and USF-2. To our knowledge, this represents the first report demonstrating the engagement of USFs in the regulation of RORgT expression. Expression of RORgT is a hallmark of Th17 development (8) . Increased RORgT mRNA levels are associated with several human pathologies related to the presence of Th17-driven inflammatory processes (22, 41) . Our observations of USF-1-and USF-2-mediated RORgT expression in human lymphocytes raise the question of what role these transcription factors may play in Th17 development. The hypothesis that USFs regulate RORgT expression in human lymphocytes is further substantiated by the increase in the USF-1 and USF-2 mRNA levels observed upon in vitro differentiation of Th17 from naive CD4 + lymphocytes that are paralleled by the increases in RORgT and IL-17 mRNAs (Fig. 7) , and by the observation that suppression of the expression of USFs significantly decreased the level of RORgT mRNA in Th17 cells (Table I ). This inhibition of RORgT expression was not associated with significant inhibition of expression of IL-17 that might be explained by upregulation of IL-17 expression by other than RORgT transcription factors such as NFAT (42) . Thus, to our knowledge, we provide in this article the first analysis of the human RORgT promoter and the first evidence of the roles of the USF-1 and USF-2 transcription factors in regulating the expression of RORgT in human lymphocytes. Furthermore, we report observations supporting the role of USF-mediated regulation of RORgT expression in the mechanism of Th17 differentiation.
USFs are known to be engaged in several processes related to maintaining lipid and glucose homeostasis (43) (44) (45) (46) . Thus, the role of USFs in the generation of the Th17 immune response is of potential interest for further understanding the proposed relationship between metabolic disorders and inflammation (47) . With regard to this hypothesis, studies on the genetic linkage of type II diabetes, a disease in which Th17 has a known pathogenetic role (48) , showed a positive association of this disease with polymorphisms in RORC (49) and a possible, although still controversial, association with polymorphisms in USF-1 (50, 51) . Although the role of USFs in the regulation of glucose metabolism alone might explain such a linkage, the novel role of USFs in the regulation of RORgT expression should now also be considered. Another feature of known USFs activities that could be of interest for a possible role of these transcription factors in Th17 differentiation is their ability to maintain a local accessibility of chromatin for genetic transcription by interacting with proteins regulating histone acetylation (52) . Recently, the upregulation of RORgT mRNA during polyclonal Th17 expansion in vitro was reported to be associated with DNA demethylation at the RORC locus (53) . Thus, it is tempting to speculate that USFs might also be engaged in maintaining the accessibility of the RORC locus necessary for RORgT mRNA transcription in differentiating Th17 cells.
